These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35172939)

  • 1. External validation of the VENUSS prognostic model to predict recurrence after surgery in non-metastatic papillary renal cell carcinoma: A multi-institutional analysis.
    Erdem S; Capitanio U; Campi R; Mir MC; Roussel E; Pavan N; Kara O; Klatte T; Kriegmair MC; Degirmenci E; Aydin R; Minervini A; Serni S; Berni A; Rebez G; Ozcan F;
    Urol Oncol; 2022 May; 40(5):198.e9-198.e17. PubMed ID: 35172939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic role of histomorphological subtyping in nonmetastatic papillary renal cell carcinoma after curative surgery: is subtype really irrelevant? A propensity score matching analysis of a multi-institutional real life data.
    Erdem S; Bertolo R; Campi R; Capitanio U; Amparore D; Anceschi U; Mir MC; Roussel E; Pavan N; Carbonara U; Kara O; Klatte T; Marchioni M; Pecoraro A; Muselaers S; Marandino L; Diana P; Borregales L; Palumbo C; Warren H; Wu Z; Calio A; Ciccarese C; Degirmenci E; Aydin R; Rebez G; Schips L; Simone G; Minervini A; Serni S; Ozcan F
    Urol Oncol; 2024 May; 42(5):163.e1-163.e13. PubMed ID: 38443238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort.
    Klatte T; Gallagher KM; Afferi L; Volpe A; Kroeger N; Ribback S; McNeill A; Riddick ACP; Armitage JN; 'Aho TF; Eisen T; Fife K; Bex A; Pantuck AJ; Stewart GD
    BMC Med; 2019 Oct; 17(1):182. PubMed ID: 31578141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison and validation of different risk models for papillary renal cell carcinoma.
    Lin H; Sun Q; Li Z; Zheng J; Zhang X; Xiong Y; Chen H; Hou Y; Xi W; Lin J
    Urol Oncol; 2023 Aug; 41(8):358.e1-358.e7. PubMed ID: 37394414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.
    Leibovich BC; Lohse CM; Cheville JC; Zaid HB; Boorjian SA; Frank I; Thompson RH; Parker WP
    Eur Urol; 2018 May; 73(5):772-780. PubMed ID: 29398265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma.
    Piccinelli ML; Tappero S; Cano Garcia C; Barletta F; Incesu RB; Morra S; Scheipner L; Tian Z; Luzzago S; Mistretta FA; Ferro M; Saad F; Shariat SF; Ahyai S; Longo N; Tilki D; Briganti A; Chun FKH; Terrone C; de Cobelli O; Musi G; Karakiewicz PI
    Eur Urol Open Sci; 2023 Jul; 53():109-115. PubMed ID: 37441347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: results of an international multi-institutional study on 2189 patients.
    Borgmann H; Musquera M; Haferkamp A; Vilaseca A; Klatte T; Shariat SF; Scavuzzo A; Jimenez Rios MA; Wolff I; Capitanio U; Dell'Oglio P; Krabbe LM; Herrmann E; Ecke T; Vergho D; Huck N; Wagener N; Pahernik S; Zastrow S; Wirth M; Surcel C; Mirvald C; Prochazkova K; Hutterer G; Zigeuner R; Cindolo L; Hora M; Stief CG; May M; Brookman-May SD
    World J Urol; 2017 Dec; 35(12):1891-1897. PubMed ID: 28836063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting recurrence and survival in patients with non-metastatic renal-cell carcinoma after nephrectomy: a prospective population-based study with multicenter validation.
    Wang Y; Xuan Y; Su B; Gao Y; Fan Y; Huang Q; Zhang P; Gu L; Niu S; Shen D; Li X; Wang B; Zhu Q; Ouyang Z; Xie J; Ma X
    Int J Surg; 2024 Feb; 110(2):820-831. PubMed ID: 38016139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and External Validation of a Novel Nomogram Predicting Cancer-specific Mortality-free Survival in Surgically Treated Papillary Renal Cell Carcinoma Patients.
    Piccinelli ML; Barletta F; Tappero S; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Luzzago S; Mistretta FA; Ferro M; Saad F; Shariat SF; Ahyai S; Longo N; Tilki D; Chun FKH; Terrone C; Briganti A; de Cobelli O; Musi G; Karakiewicz PI
    Eur Urol Focus; 2023 Sep; 9(5):799-806. PubMed ID: 37024421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology.
    Pichler M; Hutterer GC; Chromecki TF; Jesche J; Kampel-Kettner K; Rehak P; Pummer K; Zigeuner R
    J Urol; 2011 Nov; 186(5):1773-7. PubMed ID: 21944989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies.
    Rini B; Goddard A; Knezevic D; Maddala T; Zhou M; Aydin H; Campbell S; Elson P; Koscielny S; Lopatin M; Svedman C; Martini JF; Williams JA; Verkarre V; Radulescu C; Neuzillet Y; Hemmerlé I; Timsit MO; Tsiatis AC; Bonham M; Lebret T; Mejean A; Escudier B
    Lancet Oncol; 2015 Jun; 16(6):676-85. PubMed ID: 25979595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of segmental renal vein invasion on recurrence in patients with clinical T1 renal cell carcinoma undergoing partial nephrectomy.
    Yoshida T; Ohe C; Tsuzuki T; Sugi M; Kinoshita H; Tsuta K; Matsuda T
    Int J Clin Oncol; 2020 Mar; 25(3):464-471. PubMed ID: 31531786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
    Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
    Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p21-activated kinase 1 predicts recurrence and survival in patients with non-metastatic clear cell renal cell carcinoma.
    Zhu Y; Xu L; An H; Liu W; Wang Z; Xu J
    Int J Urol; 2015 May; 22(5):447-53. PubMed ID: 25711487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-11 receptor predicts post-operative clinical outcome in patients with early-stage clear-cell renal cell carcinoma.
    Pan D; Xu L; Liu H; Zhang W; Zhu Y; Xu J; Gu J
    Jpn J Clin Oncol; 2015 Feb; 45(2):202-9. PubMed ID: 25420690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma.
    Rosiello G; Larcher A; Fallara G; Giancristofaro C; Martini A; Re C; Cei F; Musso G; Tian Z; Karakiewicz PI; Mottrie A; Bertini R; Salonia A; Necchi A; Raggi D; Briganti A; Montorsi F; Capitanio U
    Urol Oncol; 2022 Jun; 40(6):271.e19-271.e27. PubMed ID: 35140049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Female Gender Predicts Favorable Prognosis in Patients With Non-metastatic Clear Cell Renal Cell Carcinoma Undergoing Curative Surgery: Results From the International Marker Consortium for Renal Cancer (INMARC).
    Fukushima H; Saito K; Yasuda Y; Tanaka H; Patil D; Cotta BH; Patel SH; Master VA; Derweesh IH; Fujii Y
    Clin Genitourin Cancer; 2020 Apr; 18(2):111-116.e1. PubMed ID: 32001181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgical Management and Oncologic Outcomes for Local Retroperitoneal Recurrence of Renal Cell Carcinoma After Radical Nephrectomy.
    Huang J; Wang Y; Zhang C; Hu X; Wang P; Shi G; Dong L; Zhang J; Kong W; Chen Y; Xia D; Guo J; Xue W; Huang Y; He Z
    Clin Genitourin Cancer; 2023 Apr; 21(2):315.e1-315.e7. PubMed ID: 36396584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Marconi L; de Bruijn R; van Werkhoven E; Beisland C; Fife K; Heidenreich A; Kapoor A; Karam J; Kauffmann C; Klatte T; Ljungberg B; Matin S; Sjoberg D; Staehler M; Stewart GD; Tanguay S; Uzzo R; Welsh S; Wood L; Wood C; Bex A
    World J Urol; 2018 Dec; 36(12):1973-1980. PubMed ID: 30069581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of tissue-based biomarker signature in clear cell renal cell carcinoma.
    Haddad AQ; Luo JH; Krabbe LM; Darwish O; Gayed B; Youssef R; Kapur P; Rakheja D; Lotan Y; Sagalowsky A; Margulis V
    BJU Int; 2017 May; 119(5):741-747. PubMed ID: 28075543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.